ATR and pancreatic neoplasm: To the best of our knowledge, Celastrol is the first characterized APE2 inhibitor that impairs APE2’s function in the ATR DDR pathway both in the Xenopus system and pancreatic cancer cells via negative regulation of ssDNA binding and catalytic function of APE2.